Skip to main content
Ab&B Bio-Tech CO., LTD. JS logo

Ab&B Bio-Tech CO., LTD. JS — Investor Relations & Filings

Ticker · 2627 ISIN · CNE1000071P9 HKEX Manufacturing
Open in API
Filings indexed 60 across all filing types
Latest filing 2026-05-13 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2627

About Ab&B Bio-Tech CO., LTD. JS

http://www.abbbio.com

Ab&B Bio-Tech CO., LTD. JS is a biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of human vaccines and biological preparations that confer active immunity. The company's mission centers on developing globally innovative vaccines and utilizing new technologies to improve traditional vaccines. Its comprehensive pipeline targets infectious diseases and includes candidates across viral, bacterial, conjugate, subunit, and mRNA platforms. The primary commercial product is the Quadrivalent Subunit Influenza Vaccine, approved for individuals aged six months and above. Advanced pipeline assets, such as the 23-valent Pneumococcal Polysaccharide Vaccine and the Freeze-dried Human Rabies Vaccine (Human Diploid Cell), have completed Phase I clinical trials. R&D operations are supported by facilities in Shanghai and Taizhou, with the company emphasizing scientific validation through publications in international journals.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - COMMENCEMENT OF PHASE I AND PHASE II CLINICAL TRIALS FOR RECOMBINANT RSV VACCINE (CHO CELL) (ADJUVANT)
Regulatory Filings Classification · 60% confidence The document is a voluntary announcement by Ab&B Bio-Tech regarding the commencement of Phase I and Phase II clinical trials for a vaccine. It contains no financial data, no management changes, no voting results, no capital transactions, no legal proceedings or M&A activity. It is a corporate update required under listing rules but does not fit any specialized category (e.g., earnings, interim report, board changes). Therefore it defaults to the general regulatory/announcement category: RNS.
2026-05-13 English
VOLUNTARY ANNOUNCEMENT - IND APPROVAL BY CHINA CDE FOR MRNA RSV VACCINE
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ab&B Bio-Tech regarding the approval of an Investigational New Drug (IND) application for their mRNA RSV vaccine by the China Center for Drug Evaluation (CDE). It includes background information about the company and the vaccine, and also mentions the continued suspension of trading of the company's shares on the Hong Kong Stock Exchange. The document is relatively short (3919 characters) and serves as a business update and regulatory announcement rather than a financial report or detailed filing. It does not contain financial statements, audit information, or detailed management discussion. It is not an earnings release, annual report, or interim report. It is also not a regulatory certification or officer attestation. The content fits best with a Regulatory Filing (RNS) as it is a general regulatory announcement informing shareholders and investors about a material business development and trading suspension, without fitting into more specific categories like capital update, management change, or legal proceedings.
2026-05-08 English
FORM OF PROXY FOR THE FIRST EXTRAORDINARY GENERAL MEETING OF 2026 TO BE HELD ON WEDNESDAY, MAY 27, 2026 AND ANY ADJOURNMENT THEREOF
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Form of Proxy for an Extraordinary General Meeting (EGM) scheduled for May 27, 2026. It includes instructions for shareholders to appoint proxies to vote on resolutions such as abolition of the supervisory committee, amendments to articles of association, appointment of directors, and appointment of auditors. The document is procedural and related to shareholder voting at a general meeting. It is not a report of voting results, nor is it a report of financial performance or management discussion. It is a solicitation document for proxy voting at a shareholder meeting. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI). The document length (7527 characters) and content confirm it is not a brief announcement or a report publication notice but a full proxy form with detailed instructions and notes.
2026-05-08 English
(1) ABOLITION OF THE SUPERVISORY COMMITTEE (2) AMENDMENTS TO THE ARTICLES OF ASSOCIATION (3) AMENDMENTS TO CERTAIN INTERNAL CORPORATE GOVERNANCE POLICIES (4) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE D
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a circular issued by the Board of Ab&B Bio-Tech CO., LTD. JS, providing detailed information about an upcoming Extraordinary General Meeting (EGM). It includes multiple agenda items such as abolition of the supervisory committee, amendments to the articles of association, amendments to internal corporate governance policies, appointment of an independent non-executive director, appointment of auditor, and the notice of the EGM itself. The document contains a letter from the Board, detailed explanations of the proposed resolutions, biographies of director candidates, and the notice of the EGM. It is not a financial report, earnings release, or audit report, but rather a comprehensive communication to shareholders about governance and meeting matters. This fits the definition of Proxy Solicitation & Information Statement (PSI), which are materials sent to shareholders to provide information and request votes for meetings such as EGMs. The document length (15,000 characters) and content confirm it is the actual circular, not just an announcement of a report. Therefore, the correct classification is PSI with high confidence.
2026-05-08 English
NOTICE OF THE FIRST EXTRAORDINARY GENERAL MEETING OF 2026
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice for the first extraordinary general meeting (EGM) of 2026 for Ab&B Bio-Tech CO., LTD. JS. It includes details about the meeting date, location, resolutions to be considered (such as abolition of the supervisory committee, amendments to articles of association, appointment of directors and auditors), voting procedures, and shareholder instructions. There are no financial statements, management discussion, or detailed financial data present. The document serves as an announcement to shareholders about the upcoming EGM and the matters to be voted on, rather than the results of the meeting or detailed reports. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2026-05-07 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2026
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 30 April 2026. It contains detailed information on movements in authorised/registered share capital, issued shares, treasury shares, public float sufficiency confirmation, and confirmations pursuant to specific listing rules of The Stock Exchange of Hong Kong Limited. The document is a regulatory submission reporting monthly share capital and shareholding movements, not a financial report, earnings release, or management discussion. It is a regulatory filing required by the exchange to ensure compliance with listing rules regarding share capital and public float. The document length is 9468 characters, which is substantive but the content is clearly a regulatory compliance report rather than a financial or management report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2026-05-04 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.